Saving Brains: the Artesunate Suppository Severe Malaria Cohort

Not Applicable

Completed

• Conditions: Cerebral malaria or other CNS infection; Infections and Infestations; Plasmodium falciparum malaria with cerebral complications

• Registration Number: ISRCTN73295852
• Lead Sponsor: Mahidol Oxford Tropical Medicine Research Unit (MORU) (Thailand)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-05-28
• Study Completion: 2017-03-01
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 6000

Inclusion Criteria

TQQ+ questionnaire, socioeconomic status, clinical history, height on:
1. Surviving children originally enrolled in Study 13
2. Male or female
3. Written informed consent by legally acceptable representative (plus assent if appropriate)
4. Willingness and ability of the participants/guardians to comply with the study tests

Detailed neurocognitive exams
1. ~30% stratified sample of the surviving study cohort meeting criteria above
2. TQQ positive children
3. >8 years of age
(Additional inclusion criteria will apply for participants who undergo EEG and/or MRI)

Exclusion Criteria

TQQ+
1. Signs of acute illness

Detailed neurocognitive exams
1. Signs of acute illness
2. Anti-malarial injection at enrolment into Study 13
(Additional exclusion criteria will apply for participants who will undergo EEG and/or MRI)

Study & Design

• Study Type: Observational
• Study Design: Not specified